載入...
Timing of First-in-Child Trials of FDA Approved Oncology Drugs
AIM: The lag time between initial human studies of oncology agents to the first-in-child clinical trials of these agents has not been defined. METHODS: We conducted a systematic analysis of time from first-in-human trials to first-in-child trials (age of eligibility of < 18 years) of agents first...
Na minha lista:
| 發表在: | Eur J Cancer |
|---|---|
| Main Authors: | , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6491224/ https://ncbi.nlm.nih.gov/pubmed/30928805 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2019.02.011 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|